Related Experiment Video
Updated: Oct 12, 2025
08:34
Left Atrial Stenosis Induced Pulmonary Venous Arterialization and Group 2 Pulmonary Hypertension in Rat
Published on: November 18, 2018
7.3K
Pulmonary Hypertension Associated with Connective Tissue Disease
1Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument Street, Room 540, Baltimore, MD 21205, USA.
Cardiology Clinics
|November 23, 2021
Summary
Pulmonary hypertension (PH) often affects patients with connective tissue disease (CTD), increasing health risks. Systemic sclerosis patients have the highest PH incidence, with pulmonary arterial hypertension posing a significant threat.
Area of Science:
- Cardiology
- Rheumatology
- Pulmonology
Background:
- Pulmonary hypertension (PH) is a serious condition involving elevated pulmonary pressures.
- It frequently complicates connective tissue diseases (CTD), leading to increased illness and death.
- Systemic sclerosis is the CTD most commonly associated with PH development.
Purpose of the Study:
- To review the types and implications of pulmonary hypertension in connective tissue disease patients.
- To highlight the risk of pulmonary arterial hypertension (PAH) in CTD, a severe form of PH.
- To discuss potential future therapeutic strategies for pulmonary vascular remodeling.
Main Methods:
- Literature review of studies on pulmonary hypertension in connective tissue diseases.
- Analysis of PH incidence and types within various CTDs.
- Examination of the association between CTD and pulmonary arterial hypertension.
Main Results:
- The incidence of PH varies significantly across different CTDs.
- Patients with systemic sclerosis exhibit the highest risk of developing PH.
- CTD patients are susceptible to various forms of PH, including PAH, left heart disease, and respiratory disease-related PH.
Conclusions:
- Pulmonary hypertension is a critical complication of connective tissue diseases, particularly systemic sclerosis.
- Pulmonary arterial hypertension in CTD patients carries a high risk of morbidity and mortality.
- Targeting pulmonary vascular remodeling holds promise for future treatments to improve patient outcomes.
Related Concept Videos
01:30Pulmonary Hypertension: Classification and Pathogenesis
319
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
319
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
3.0K
Understanding the variety of primary symptoms and systemic complications that characterize chronic obstructive pulmonary disease (COPD) is crucial for healthcare professionals.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
3.0K
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
281
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
281
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
3.3K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
3.3K
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
376
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
376
01:23Rheumatic Heart Disease I: Introduction
87
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
87